Comparative Study of Nasal Symptoms and Pulmonary Function Tests Post FESS in Ethmoidal Polyposis

Gudiseva, Amrutha; Ramaswamy, Balakrishnan; Singh, Rohit; Dalakoti, Pooja

doi:10.1007/s12070-018-1422-4

Cited by 1 publication

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NP history alone continued to predict an enhanced FEV1 response. 28,29 4. Atopic/IgE status was not a predictor of clinical outcomes.…”

Section: Discussionmentioning

confidence: 99%

An early Indian experience with benralizumab - A compendium on severe asthma cases: a case series

Talwar,

Yadav,

Maturu

et al. 2023

F1000Res

View full text Add to dashboard Cite

Background: Severe eosinophilic asthma (SEA), one of the phenotypes of asthma that is characterized by elevated blood eosinophil counts, is a common cause of uncontrolled asthma. Patients with SEA often experience severe persistent symptoms and have frequent exacerbations despite optimal inhaler therapy. They also have poor lung function and quality of life (QoL). Benralizumab (Fasenra), a monoclonal antibody, has been approved for managing cases of SEA. This series of six cases, the first of its kind from India, aims to add to the real-world evidence of benralizumab in India. Methods: Benralizumab 30 mg (once in four weeks for the first three doses followed by a dose every eight weeks for two years) was administered in six patients with symptoms of cough, breathlessness on exertion, and wheezing, diagnosed with SEA. The following were the endpoints assessed: (i) overlap between high immunoglobulin E (IgE) and eosinophilic asthma; (ii) reduction of exacerbations; (iii) withdrawal of oral corticosteroids; and (iv) improvement in lung function and QoL. Results: In all cases, management with benralizumab resulted in optimal clinical and functional improvement, a decline in systemic steroid use, and improved QoL. Conclusions: The cases presented here are the first of their kind in the Indian asthmatic population with all SEA patients demonstrating significant improvement in symptoms with the use of benralizumab.

show abstract

“…NP history alone continued to predict an enhanced FEV1 response. 28,29 4. Atopic/IgE status was not a predictor of clinical outcomes.…”

Section: Discussionmentioning

confidence: 99%

An early Indian experience with benralizumab - A compendium on severe asthma cases: a case series

Talwar,

Yadav,

Maturu

et al. 2023

F1000Res

View full text Add to dashboard Cite

show abstract

Comparative Study of Nasal Symptoms and Pulmonary Function Tests Post FESS in Ethmoidal Polyposis

Cited by 1 publication

References 11 publications

An early Indian experience with benralizumab - A compendium on severe asthma cases: a case series

An early Indian experience with benralizumab - A compendium on severe asthma cases: a case series

Contact Info

Product

Resources

About